Scientists have finished a pioneering clinical trial regarding Pfizer’s Sunitinib (Sutent), which results in indicating success in using an adjuvant treatment for renal cancer patients that can reduce reoccurrence.
Results released at ESMO 2016 demonstrated that by taking Sunitinib orally for a year, there was a reduction in cancer reoccurrence for individuals who had a kidney removed.
Sunitinib is a targeted therapy – a protein-tyrosine inhibitor – designed to inhibit tumor growth. According to its manufacturer Pfizer, the following are indicators for the use of Sunitinib:
- Treatment of Advanced Kidney (Renal) Cancer
- Treatment of GIST (gastrointestinal Stromal Tumor), a rare form of cancer of the stomach bowel. Sunitinib is used when a medication called Gleevec (Imatinib Mesylate) failed to stop tumor growth or a patient cannot take Gleevec.
- Treatment of a kind of Pancreatic Cancer known as “Pancreatic Neuroendocrine Tumors” (pancreatic NET) that have progressed and cannot be treated with surgery.
Researchers conducted a double-blind test with over 600 participants all having Stage T3 Renal Cell Carcinoma. Individuals who received the Sunitinib orally as opposed to the placebo enjoyed a high rate of survival with no reoccurrence. Though there was a calculable increase in side effects exhibited, it is noted by researchers that they were manageable and had no significant influence on the quality of life.
Individuals suffering from “locally” advanced renal cancer are statistically susceptible to relapses at rates as high as 50% over a five year period with renal cancer claiming over 120,000 lives every year. By increasing the amount of time an individual can be “disease-free” and an overall reduction in relapse, it is a big advance for renal cancer treatment and individuals suffering from renal cancer.